{"id":21536,"date":"2026-10-19T15:42:18","date_gmt":"2026-10-19T15:42:18","guid":{"rendered":"https:\/\/veilles-affaires-sociales.fr\/?p=21536"},"modified":"2026-10-19T15:42:18","modified_gmt":"2026-10-19T15:42:18","slug":"discours-du-commissaire-varhelyi-a-la-semaine-de-linnovation-de-lamiif-association-mexicaine-des-industries-de-la-recherche-pharmaceutique-titre-traduit-en-francais-par-lia","status":"publish","type":"post","link":"https:\/\/veilles-affaires-sociales.fr\/?p=21536","title":{"rendered":"Discours du commissaire V\u00e1rhelyi \u00e0 la Semaine de l\u2019innovation de l\u2019AMIIF (Association mexicaine des industries de la recherche pharmaceutique) (titre traduit en fran\u00e7ais par l&rsquo;IA)"},"content":{"rendered":"<p>La source pr\u00e9sente un discours prononc\u00e9 \u00e0 Mexico le 20 octobre 2026 par un repr\u00e9sentant de la Commission europ\u00e9enne, \u00e0 l\u2019invitation de l\u2019association mexicaine des industries de recherche pharmaceutique. L\u2019intervention porte sur la coop\u00e9ration entre l\u2019Union europ\u00e9enne (UE) et le Mexique dans le domaine pharmaceutique, avec un accent sur l\u2019innovation, la recherche clinique, la r\u00e9glementation des m\u00e9dicaments et l\u2019acc\u00e8s aux traitements.<\/p>\n<p>Le discours souligne le r\u00f4le de la Commission europ\u00e9enne en mati\u00e8re de politique pharmaceutique, en lien avec les autorit\u00e9s r\u00e9glementaires europ\u00e9ennes et les \u00c9tats membres de l\u2019UE. Il met en avant l\u2019importance de cadres r\u00e9glementaires pr\u00e9visibles et fond\u00e9s sur des donn\u00e9es scientifiques pour soutenir l\u2019innovation tout en garantissant la s\u00e9curit\u00e9 des patients. Le secteur pharmaceutique est pr\u00e9sent\u00e9 comme strat\u00e9gique \u00e0 la fois pour la sant\u00e9 publique et pour la comp\u00e9titivit\u00e9 \u00e9conomique.<\/p>\n<p>L\u2019intervenant insiste sur la coop\u00e9ration internationale, en particulier avec le Mexique, dans plusieurs domaines : harmonisation ou convergence r\u00e9glementaire, participation \u00e0 des essais cliniques internationaux, partage de donn\u00e9es scientifiques, renforcement des capacit\u00e9s r\u00e9glementaires et promotion de standards de qualit\u00e9 \u00e9lev\u00e9s. Le r\u00f4le des autorit\u00e9s mexicaines de sant\u00e9 et de r\u00e9gulation, ainsi que des associations industrielles, est mentionn\u00e9 comme central pour d\u00e9velopper ces coop\u00e9rations.<\/p>\n<p>Plusieurs enjeux de politique publique sont mis en avant : acc\u00e8s \u00e9quitable aux m\u00e9dicaments innovants, \u00e9quilibre entre incitations \u00e0 l\u2019innovation et soutenabilit\u00e9 des syst\u00e8mes de sant\u00e9, renforcement des cha\u00eenes d\u2019approvisionnement et de la s\u00e9curit\u00e9 d\u2019approvisionnement en m\u00e9dicaments, besoin de cadres stables pour attirer les investissements en recherche et d\u00e9veloppement. Le discours \u00e9voque \u00e9galement la n\u00e9cessit\u00e9 de tirer des enseignements des crises sanitaires r\u00e9centes pour mieux pr\u00e9parer les syst\u00e8mes de sant\u00e9 et les dispositifs de production pharmaceutique.<\/p>\n<p>L\u2019UE est pr\u00e9sent\u00e9e comme souhaitant renforcer ses partenariats avec des pays tiers, dont le Mexique, autour de priorit\u00e9s communes : soutien \u00e0 la recherche biom\u00e9dicale, d\u00e9veloppement de th\u00e9rapies innovantes, am\u00e9lioration de l\u2019\u00e9valuation des technologies de sant\u00e9 et coop\u00e9ration r\u00e9glementaire. Ces orientations sont reli\u00e9es \u00e0 des objectifs plus larges de sant\u00e9 publique, de croissance et d\u2019emploi qualifi\u00e9 dans le secteur de la sant\u00e9 et de l\u2019industrie pharmaceutique.<\/p>\n<p>Le discours adopte un ton ouvert \u00e0 la poursuite de dialogues techniques et politiques avec les autorit\u00e9s mexicaines et les acteurs industriels, sans annoncer de mesures juridiques concr\u00e8tes ni de nouveaux instruments pr\u00e9cis. Les perspectives \u00e9voqu\u00e9es restent g\u00e9n\u00e9rales, centr\u00e9es sur une intensification de la coop\u00e9ration, le renforcement des capacit\u00e9s r\u00e9glementaires et le soutien \u00e0 l\u2019innovation pharmaceutique dans un cadre multilat\u00e9ral et bilat\u00e9ral, avec une attention \u00e0 l\u2019acc\u00e8s aux soins et \u00e0 la soutenabilit\u00e9 des syst\u00e8mes de sant\u00e9.\u00a0(contenu r\u00e9sum\u00e9 en fran\u00e7ais par l&rsquo;IA)<a href=\"https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/en\/speech_26_2202\" target=\"_blank\" class=\"feedzy-rss-link-icon\">Lire la Suite<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>La source pr\u00e9sente un discours prononc\u00e9 \u00e0 Mexico le 20 octobre 2026 par un repr\u00e9sentant de la Commission europ\u00e9enne, \u00e0 l\u2019invitation de l\u2019association mexicaine des industries de recherche pharmaceutique. L\u2019intervention [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10686,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[31,2],"tags":[235,227,226],"class_list":["post-21536","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-politiques-europeennes-sante-social-travail","category-sante-publique-et-systeme-de-soins","tag-commission-europeenne","tag-ia","tag-sources-etrangeres"],"_links":{"self":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/21536","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21536"}],"version-history":[{"count":0,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/21536\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/media\/10686"}],"wp:attachment":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21536"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21536"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}